CeriBell, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CBLL research report →
Range $26 – $29
Price Chart
About the company
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments.
- CEO
- Xingjuan Chao
- IPO
- 2024
- Employees
- 327
- HQ
- Sunnyvale, CA, US
Get TickerSpark's AI analysis on CBLL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.06B
- P/E
- -13.39
- PEG
- 0.55
- P/S
- 9.28
- P/B
- 8.51
- EV/EBITDA
- -13.87
- Div Yield
- 0.00%
- Gross Margin
- 89.26%
- Op Margin
- -69.79%
- Net Margin
- -67.96%
- ROE
- -54.53%
- ROIC
- -54.37%
Latest fiscal year · YoY change
- Revenue
- $89.06M+36.1%
- Gross Profit
- $78.27M+37.9%
- Op Income
- $-58,402,000
- Net Income
- $-53,412,000-32.0%
- EPS
- $-1.46-29.2%
- OCF Growth
- -16.5%
- FCF Growth
- -14.3%
- 52W High
- $28.89
- 52W Low
- $13.61
- 50D MA
- $25.66
- 200D MA
- $21.15
- Beta
- 0.86
- RSI (14)
- 56
- Avg Volume
- 446.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CeriBell posted another strong growth quarter, with revenue up about 30% year over year and management pointing to record utilization, expanding accounts, and a new delirium launch as the setup for 2027.· November 3, 2026
- Q3 revenue was $29.3 million, up about 30% year over year, with both new account adds and deeper usage at existing accounts driving growth.
- Active accounts increased by a record 35 in the quarter to 747, while usage per account reached a new high and grew in double digits year over year.
- Gross margin improved to 90% from 88%, and management expects margins to stay in the high 80% range based on tariff policy and inventory.
- Full-year 2026 revenue guidance was raised to $115 million-$117 million, implying 29%-31% growth, while the company said newer products will contribute more meaningfully in 2027.
- Delirium was launched as a software upgrade at no incremental subscription fee, and management said the pilot showed meaningful utilization and commercial impact, but broad adoption will take time.
Total revenue for Q3 2026 was $29.3 million, up approximately 30% from $22.6 million in Q3 2025 and up 4% sequentially. Product revenue was $22.2 million, up 31% from $17 million, and subscription revenue was $7.1 million, up 28% from $5.6 million. Gross margin was 90% versus 88% a year ago. Net loss was $21.4 million, or $0.55 per share, compared with a net loss of $13.5 million, or $0.37 per share, in Q3 2025; adjusted EBITDA loss was $12.1 million versus $9.2 million. Cash, cash equivalents and marketable securities were $117.5 million at September 30, 2026. For 2026, management raised revenue guidance to $115 million-$117 million from $114 million-$117 million, representing 29%-31% growth, and said this does not include material contributions from neonate, pediatric or delirium products, which are expected to matter more in 2027.
Jane Chao said Q3 validated CeriBell’s core seizure business as a durable growth engine, with record account additions, record utilization, and continued department expansion. She emphasized that the company is also building several growth vectors at once: strategic account management, VA/DoD expansion, neonate, and now delirium. Her tone was upbeat and confident, framing 2027 as a pivotal year when seizure, delirium, and the Omni hardware platform should come together into a broader EEG-as-a-vital-sign strategy.
Scott Blumberg walked through the quarter’s financials, highlighting $29.3 million of revenue, 90% gross margin, and a $21.4 million net loss. He noted operating expenses of $46.9 million, including $25 million of sales and marketing, $14.5 million of G&A, and $7.4 million of R&D; noncash stock-based compensation was $7.1 million, and litigation-related expenses were $1.1 million. He also said cash and marketable securities totaled $117.5 million and that the company remains committed to achieving cash flow breakeven with cash on hand; with the new revolver-first structure, interest expense is expected to fall to less than $1 million annually. Gross margins are expected to remain in the high 80% range going forward.
Analysts focused on why subscription revenue did not increase as much as product revenue, and management said nothing fundamental changed: product remains the majority of revenue, while subscription is still a durable long-term growth driver. Questions around delirium centered on how big and how fast the opportunity could be, but management said it is too early to quantify and will give more granular 2027 guidance later; they also said the launch is intended to leverage the existing sales force and is not tied to required volume commitments. On VA, management said the new commitment is roughly in line with last year and should roll into the account base over the next 2-3 quarters, while usage tends to start below average but improves with experience. Analysts also pressed on same-store growth definitions and expense trends, and management said utilization is the core metric, the infrastructure investments for 2027 are largely already made, and future spending will be reviewed carefully against the goal of breakeven with cash on hand.
The call showed broad operating momentum: record account adds, record utilization, improving margins, and a raised full-year revenue guide. Management sounded confident that delirium can expand usage in existing accounts and create a new revenue stream over time, while Omni and new algorithms add additional long-term upside.
Management repeatedly said delirium is still too early to quantify, so the size and timing of the revenue opportunity remain uncertain. Expenses are still growing faster than revenue, net loss widened year over year, and broad adoption of delirium and newer products is expected to take time rather than hit all at once.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 66.6%
- Shares Outstanding
- 38.84M
- Float Shares
- 25.87M
of shares held by institutions
126 13F filers
Buy/sell ratio 0.45. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 6.33M | ▲ 634.52K |
| Red Tree Management, LLC | 2.21M | 0 |
| Blackrock, Inc. | 2.11M | ▲ 177.44K |
| Tpg Gp A, LLC | 2.04M | ▼ 1.73M |
| Vanguard Group Inc | 1.51M | ▲ 34.05K |
| Vanguard Capital Management LLC | 1.35M | ▲ 221.57K |
| Kcm Capital Inc | 1.15M | ▲ 25.00K |
| Federated Hermes, Inc. | 939.25K | ▼ 349 |
| Franklin Templeton Inc | 922.31K | ▲ 3.96K |
| Adage Capital Partners Gp, L.L.C. | 900.00K | 0 |
| Timessquare Capital Management, LLC | 782.90K | ▲ 2.35K |
| Geode Capital Management, LLC | 706.57K | ▲ 38.44K |
Held by 134 ETFs
Biggest fund positions in CBLL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Parvizi Josef | sell | 25,000 |
| Nov 12, 26 | BURKE WILLIAM W | other | 18,000 |
| Nov 12, 26 | BURKE WILLIAM W | sell | 16,845 |
| Nov 12, 26 | BURKE WILLIAM W | sell | 1,155 |
| Nov 12, 26 | BURKE WILLIAM W | other | 18,000 |
| Nov 9, 26 | Taylor Joseph Michael | sell | 10,200 |
| Nov 2, 26 | Woo Raymond | other | 23 |
| Nov 2, 26 | Woo Raymond | other | 4,864 |
| Nov 2, 26 | Woo Raymond | sell | 4,887 |
| Nov 2, 26 | Woo Raymond | other | 4,864 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CBLL coverage
Recent articles, reports, and earnings notes.
No research on CBLL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CBLL report →CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 3
CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 3
CeriBell Q3 Earnings Call Highlights
marketbeat.com · Nov 3
Ceribell Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 3
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
globenewswire.com · Nov 2
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
globenewswire.com · Oct 28
Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
globenewswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.